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CHAPTER I 
 
 INTRODUCTION 
 
Overview 
 This chapter will introduce the drug discovery process as well as the pitfalls 
associated with it.  Techniques employed to address biological problems associated with 
drug discovery are introduced with an emphasis placed on proteomics.  In particular, 
direct tissue MALDI MS is described as well as sample preparation methods associated 
with this technique.  Finally, an overview of the work contained in this thesis is 
presented. 
 
Drug Discovery 
The drug discovery process is a laborious task for the researcher and an expensive 
endeavor for the pharmaceutical industry.  It has been proposed that it can take up to 15 
years and $800 million to see a drug from bench to bedside [1].  Continued development 
of drug candidates tends to bottleneck at the pre-clinical or clinical trial stage because a 
molecule can behave differently in vivo than it does in vitro.  Possible side effects of 
drugs are not seen until they are introduced into a living organism.  It is here that toxicity 
becomes a problem.  Kidneys are particularly susceptible to toxins because of their role 
in filtering the blood.  Monitored indicators of nephrotoxicity, such as changes in serum 
creatinine levels or cellular morphology, often are not detected until the onset of toxic 
nephropathy [2].   Nephrotoxcity will be further discussed in chapter II.  If mechanisms 
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of toxicity were more thoroughly understood, then more precautions could be taken at the 
front end of the process thereby saving time and money.  Several „omics techniques have 
been used to assess effects of drug treatment, thereby shedding insight into mechanisms 
of toxicity.  Biological changes associated with drug treatment can be monitored at the 
genomic (DNA and mRNA expression profiling), proteomic (protein profiling in tissues 
and surrounding biofluids) and metabolomic levels (monitoring endogenous metabolites 
in tissues and surrounding biofluids).  The differences in the strategies have been 
described as examining what could happen (genomics), what is happening (proteomics) 
and what has happened (metabonomics) [3].  To truly ascertain and understand what is 
causing the toxicity, it is important to know what is happening.  For this reason the work 
in this thesis utilized proteomics techniques to assess toxicity. 
 
Proteomic Techniques 
 Proteomics has the advantage of utilizing various techniques in a high-throughput 
manner to identify a protein and its function.  One of the most commonly used methods 
involves 2D gels.  Tissue or cell extracts are separated first by their isoelectric point and 
then further separated by molecular weight on a 1D gel.  A spot corresponding to the 
protein of interest is then excised and digested with an enzyme, typically trypsin, and 
then analyzed by mass spectrometry to identify the protein.  Quantification can be done 
in this same manner with the aid of fluorescent cyanine dyes known as Cy3 and Cy5 [4].  
Two protein extracts are labeled with the dyes, mixed and then run on the same gel.  The 
difference in the intensity of the corresponding dyes as determined by fluorescence can 
be visualized and the relative amounts of proteins determined in a process called 2D-
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difference gel electrophoresis (DIGE).  There are several limitations associated with this 
technology including sensitivity and types of proteins visualized.   Typically the most 
abundant proteins are indentified in this type of analysis [5].  Additionally, if the protein 
of interest does not enter the gel (insoluable or larger molecular weight proteins) or easily 
exits the gel as is the case with smaller molecular weight proteins, identification will not 
be achieved [6]. 
 Multidimensional liquid separation techniques coupled to mass spectrometry are 
also used to identify proteins in a biological system.  This process is termed 
multidimensional protein identification technology (MudPIT) [7].  In MudPIT analysis 
extracts are first enzymatically digested and then separated based on hydrophobicity or 
charge on a packed column followed by on-line mass spectrometry analysis.  
Quantification can be done with the use of isotopically labeled standards or reagents [8, 
9]. This technique referred to as “shot-gun analysis,” attempts to identify everything in a 
sample without any separation prior to digestion.  This then can become a limitation if the 
protein of interest is not abundant enough to generate peptides to get a confident 
identification. 
 A limitation of both techniques is the need for homogenization and extensive 
sample preparation.  The spatial integrity of the tissue as well as any corresponding 
information is lost with these methods.  Great insight can be gained by not only knowing 
the identification of a protein but the localization as well.  Direct tissue analysis by 
MALDI MS allows for the investigation of disease while maintaining the spatial integrity 
of the tissue with minimal sample preparation.  This technique is described further below. 
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Direct Tissue Analysis by MALDI MS 
 
Background 
MALDI MS, introduced in the late 1980s [10, 11], has become an enabling 
analytical technology to study proteins in biological systems because of its molecular 
specificity and high-throughput capabilities [12, 13].  One of the more recent 
developments to this technology is its application to direct tissue analysis for both 
molecular profiling and imaging [14]. The technology allows for the analysis of 
molecules in tissues without the need for target specific reagents such as antibodies or the 
need for tissue homogenization, thereby maintaining the integrity of the tissue sample 
and allowing assessment of molecular spatial distribution.   
 The principles of MALDI MS have been described [15-19]. In brief, the analyte 
of interest is mixed with an energy absorbing compound (matrix) on a MALDI target 
plate.  As the solvent evaporates, the analyte co-crystallizes with the matrix.  Inside the 
mass spectrometer, molecules are desorbed from the sample by irradiation with a UV 
laser.  In this process, analytes become protonated and primarily give rise to [M+H]
+
 ions 
that are subsequently measured according to their mass-to-charge (m/z).  Typically, the 
time-of-flight analyzers are employed to measure m/z of ions (Figure 2).   
 MALDI MS can be used to profile molecules in a tissue section.  This refers to 
the process of analyzing a small number of discrete spots deposited throughout the 
sample.  Additionally it can be used to image a sample, or systematically raster across a 
tissue section to produce an ordered array of spots.  In the latter, the laser performs a 
raster over the tissue surface in a pre-defined two-dimensional array or grid, generating a 
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full mass spectrum at each grid coordinate.  Mass spectra acquired in this manner 
typically display ions in the m/z range of 500 to over 100,000, corresponding to many 
hundreds of different molecules present in the tissue.  The coordinates of the irradiated 
spots are used to generate two-dimensional ion density maps, or images, that represent 
individual m/z values with their corresponding intensities (Figure 3).  Likewise, drug 
analysis in tissue can be accomplished by monitoring the protonated drug or its 
metabolites and their corresponding fragments, at each discrete coordinate of such an 
array. 
Direct tissue analysis by MALDI MS has been used to detect drugs and their 
metabolites [20-24] intact proteins and peptides [25-27] and recently phospholipids [28] 
directly from tissue.  Profiling/imaging MS has been used to study molecular aspects of 
cancer, providing tumor-specific markers as well as diagnostic and prognostic-specific 
markers [29, 30].  With regards to the kidney, our laboratory has applied 
profiling/imaging methodologies to glomerulosclerosis [31], clear cell renal cell 
carcinoma [32] and drug-induced renal toxicity [33].   
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Figure 1.  Transthyretin as a marker of gentamicin nephrotoxicity.   Rats were dosed 
with gentamicin once daily for seven days, sacrificed and their kidneys excised.  
Differential protein expression was compared between control and dosed kidneys using 
IMS.  This figure shows the image analysis of m/z 12959 differentially expressed in the 
cortex of dosed tissue with corresponding average peaks in the spectrum.  Figure adapted 
from [33] with permission.  
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Figure 2.  MALDI-TOF Schematic.  A sample is irradiated with a brief laser pulse and 
molecules are desorbed from the surface.  Energy is absorbed by the matrix and 
transferred to the analyte, which becomes protonated and is then accelerated down a field 
free drift tube.  Ions collide with a detector at the end of this tube and their time-of-flight 
is measured and converted to a mass-to-charge ratio (m/z).  Figure adapted from [32] 
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Figure 3.  Images generated by Imaging MALDI MS. A) Optical hematoxylin and 
eosin stained (top) and overlaid ion images (bottom) of a normal rat kidney section.  
Shown are three ions given false color to show localization (pink: m/z 8451 in the cortex, 
green: m/z 8565 in the outer medulla, blue: m/z 4965 localized primarily in the inner 
medulla).  B) Optical hematoxylin and eosin stained (top) and ion images (bottom) of a 
human clear cell renal cell carcinoma tissue section with tumor and adjacent non-tumor 
tissue.  Shown are two overlaid ions represented by false color (red: m/z 4965 localized 
to tumor, green: m/z 6592 in non-tumor cortex).   Figure reprinted with permission from 
[32] 
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Sample Preparation for Profiling and Imaging Tissues by MS 
 Direct MS analysis is usually performed on tissues that have been excised and 
immediately frozen in liquid nitrogen in order to maintain tissue morphology and 
minimize molecular degradation.  Maintaining the integrity of the tissue throughout this 
process maximizes the information obtained in the analyses by ensuring that the original 
three-dimensional structure is not compromised and the molecular species monitored 
have not been altered as a result of the sample procurement and preparation process. 
 Typically, analysis is performed on frozen tissue although workflow has been 
developed for formalin fixed paraffin embedded samples [34, 35] and ethanol preserved 
specimens [36].  Tissues are sectioned in a cryostat, if necessary, using a small amount of 
optimum cutting temperature (OCT) media on the cutting block and for anchoring 
support.  Preferably, tissue should not be embedded in the polymer media as surface 
contamination with polymer caused by the cutting process tends to reduce ionization 
efficiency.  A cryostat temperature of between -15
 o
C to -25
 o
C is generally optimal for 
sectioning kidney tissue.  Sections are generally cut at 12 µm thickness but may range 
between 10-20 µm depending on the application [13, 21].  After cutting, sections are 
thaw-mounted onto a MALDI target plate and/or washed or allowed to dry in a vacuum 
desiccator. 
 It is advantageous to wash tissue sections that are rich in salts and other 
contaminants as well as hemoglobin prior to matrix deposition because these species can 
contribute to a high spectral baseline and generalized signal suppression.  Because of the 
kidney‟s role in filtration of blood, washing kidney sections removes excess hemoglobin 
and salts and enhances signal quality.  The conventional tissue washing method involves 
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two separate 70% ethanol submersions for 20-30s followed by 10-15s in 95% 200-proof 
ethanol (or 100% reagent grade ethanol).  Ethanol is a known tissue fixative in histology 
[37] and delocalization of proteins appears not to be significant; however it is noted that 
proteins soluble in these aqueous solutions may be removed during the washing step.  
Previous studies have indicated minimal protein loss during this process, but the washing 
procedure should be confirmed for each tissue type [38, 39].    
 Selection of the matrix/solvent combination for direct tissue analysis depends on 
the molecular weight, hydrophobicity, and salt content of the analyte.  Typically, 3,5-
dimethoxy-4-hydroxycinnamic acid (sinapinic acid, SA) is favorable for proteins (MW > 
2 kDa), and α-cyano-4-hydroxycinnamic acid (CHCA) is optimal for peptides (500-2000 
Da).  Small molecule analysis, including drugs and lipids, is usually performed with 2,5-
dihydroxybenzoic acid (DHB).  The optimal matrix concentration range is 10-30mg/ml 
SA for protein analysis and 10-20 mg/ml CHCA for peptide analysis.  The usual matrix 
solvent is 50% acetonitrile (ACN) with 0.1% trifluoroacetic acid (TFA).  More nonpolar 
solvents such as methanol or isopropanol can be used for more hydrophobic matrices. 
The optimal matrix/solvent combination may vary between tissue types and analytes and 
must be assessed for each study. 
 Various methods of matrix deposition on thin tissue sections have been 
successfully employed.  For tissue profiling, matrix can be manually deposited either 
with a pipette or pulled glass capillary.  Syringe pumps provide an alternative, more 
automated approach with higher reproducibility and smaller matrix spot diameters.  
Robotic deposition offers superior reproducibility, smaller matrix spot diameters and a 
higher throughput platform, and  also allows for the ability to perform histology-directed 
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analyses [40] and imaging.  Two types of robotic devices, an acoustic spotter [38] and a 
chemical inkjet printer [41], have been successfully utilized for tissue profiling and 
imaging.  General matrix deposition guidelines for both robotic types have been 
described [38, 41] but for each tissue type, method optimization is recommended to 
determine the number of matrix drops and passes required to obtain high quality spectra. 
In some cases matrix seeding may be desired to aid in the crystallization process [38]. 
The current minimum spot-to-spot spacing achievable with commercial robotic spotters is 
in the range of 100-200 μm. For applications that require a resolution higher than 150 
μm, spray coating may be used.  A spray coating device may be as simple as a glass thin 
layer chromatography (TLC) spray nebulizer that generates and sprays fine droplets of 
matrix under slight positive pressure, or automated spray devices.  The matrix solution 
must wet the tissue surface to ensure co-crystal formation between matrix and analyte.  
For manual spraying methods, a one minute delay between passes provides sufficient 
drying time.  Multiple passes are necessary to coat the entire tissue, but over-coating can 
suppress analyte signal.  The matrix coverage can be monitored as necessary under a 
microscope.  Specific matrix conditions used in this research will be outlined in the 
corresponding experimental methods section. 
 
Histology Directed MS Analysis 
Region specificity is important for analysis of heterogeneous tissue types such as 
kidney.  One MALDI compatible method to accomplish this is to stain tissues using 
cresyl violet stain or other suitable stains (H&E stains give poor MS results), allowing 
histology and MS analysis to be performed on the same tissue section with minimal 
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interference in signal quality [42].  This method usually requires that tissue sections be 
applied to a conductive glass slide to obtain histo-pathological detail.  A new method, 
histology-directed MS analysis, utilizes digital imaging to merge traditional 
histopathology, or hematoxylin and eosin tissue staining, with tissue profiling (Figure 4).  
Details of this methodology have been reported [40]. In brief, areas of interest on a 
stained tissue section are selected for MS analysis.  The coordinates of these areas are 
transferred to a robotic matrix spotter and then to the mass spectrometer.  This allows the 
profiles and other data processing algorithms such as statistical analysis, to be directly 
linked to the histological image and subsequently links the molecular profiles and 
histopathology. 
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Figure 4. Histology-directed MS sample preparation for tissue analysis.  A 
pathologist or researcher systematically selects discrete cellular areas (spots) of interest 
on a stained tissue section. The coordinates of the spots are transferred to the robotic 
spotter for matrix deposition on a co-registered serial section with subsequent laser 
irradiation of these spots (outlined in black for visualization) to give mass spectra.  Figure 
reprinted with permission from [32]. 
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MS Analysis 
The mass spectral acquisition methods used in direct tissue analysis are performed 
in an automated fashion. When profiling or imaging discrete matrix spots, mass spectra 
are obtained by performing a raster over the area of interest on the tissue.  The number of 
spectra obtained and averaged from a single spot on tissue depends on how many shots 
are needed to produce a spectrum having a high signal-to-noise.  Most experiments sum 
between 250 and 500 spectra on a single spot about 150 um in diameter whereas data 
acquired from spray coated samples will acquire fewer spectra at a single position. 
 Spectral pre-processing is carried out on the acquired data to reduce inter- and 
intra-experimental variance. Such variations may be produced from the ionization 
process, background noise, and calibration offsets that result from biological or sample 
preparation differences.  Mass spectra are processed by removing background noise, 
normalizing intensities, and performing a final mass realignment utilizing common peaks 
found in the spectra. The latter is primarily used for profiling experiments in which 
multiple sample groups are being compared, enhancing the efficacy of statistical analyses 
for determining biological patterns and changes in these patterns. Generally, imaging 
applications utilize background subtraction and normalization to significantly enhance 
the image quality. Illustrations of these processes have been presented [43]. 
 
Data Analysis 
 The large, complex datasets produced by these experiments require robust 
bioinformatics tools to assess spectral patterns and decipher molecular species that 
differentiate one group of samples from another.  MS data from each group are 
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compared, to determine spectral features (peaks) that are significantly different between 
the two subject groups.  The experimental design and biostatistical methods utilized are 
critical to the success of such analyses.  Many of the algorithms used to decipher the vast 
amount of proteomic information were initially employed for genomic microarray 
experiments and have been adapted for proteomic dataset analyses [44-47].  The work 
presented herein utilized the Significance Analysis of Microarrays (SAM).  The SAM 
statistic utilizes feature specific t-tests to determine the relationship between that 
feature‟s expression and the experimental conditions, expressed as a response variable.  
Multiple permutations are performed to assay the relationship between the two.  This type 
of analysis is beneficial in that it does not make parametric assumptions about the data 
(Tuscher 2001).  The algorithm estimates the rate of the median number of features 
falsely assigned as significant as a false discovery rate.   
 
Protein Identification 
 Identification of statistically relevant mass spectral peaks is necessary to gain 
insight into biological processes.  There are two approaches to protein identification.  The 
top-down approach involves ionization and gas phase fragmentation of intact purified 
proteins of interest in the mass spectrometer. The bottom-up approach utilizes MS to 
identify peptides obtained from protease digestion of that protein, often in a mixture of 
other proteolytic fragments.  The resulting mass spectra are searched against theoretical 
protein/peptide databases for corresponding sequence patterns.  Searches are performed 
using conventional algorithms such as MASCOT and Sequest, [48, 49].  When possible, 
manual validation of reported identifications is recommended to reduce false positives.   
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 Commonly, the bottom-up strategy is used due to its robustness.  Many proteins 
are not amenable to intact fragmentation due to their size. The bottom-up strategy 
involves homogenization of the tissue followed by reversed-phase liquid chromatography 
(RP-LC) separation, where the eluate is continuously collected into fractions.  Fractions 
are vacuumed to dryness, dissolved in 40% acetonitrile with 0.1% TFA, spotted onto a 
MALDI plate and analyzed for the fractions containing the peptides of interest.  Based on 
the complexity of the fraction, one can enzymatically digest the entire fraction or further 
separate the mixture by one dimensional gel electrophoresis followed by excision and 
enzymatic digestion of the band of interest.  Peptides are then subjected to further 
separation and fragmentation by RP-LC-tandem MS analysis and subsequent database 
searches.  
 
Research Objectives 
The use of antibiotics to treat gram negative bacterial infections is greatly 
hampered due to their propensity to exert damage on the kidney.  Currently, this damage 
is detected by techniques that lack the sensitivity and specificity needed to be useful in 
clinical settings.  Therefore, there is a need for a wider range of markers as well as those 
that will serve as early indicators of damage.  Recently, direct tissue MALDI MS was 
used to identify transthyretin as a marker of gentamicin induced nephrotoxicity [33].  
Direct tissue MALDI MS analysis is a valuable tool to differentiate various disease states.  
Its use to detect early protein markers of drug toxicity is explored in chapter II of this 
thesis.   
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 Upon analysis of the various protein markers identified as indicators of damage, 
we discovered a modified form of ubiquitin.  A truncated, desGG form of ubiquitin was 
found to be decreased as a result of drug treatment.  Further exploration of this protein 
led us to discover that this modification was originally thought to be an experimental 
aritifact [50].  The history of the discovery of ubiquitin and this product is discussed 
further in chapter III.  To further characterize and explore the nature of this modified 
ubiquitin we performed analyses to determine the enzyme responsible for the truncation, 
to examine the effect of our sample handling on presence of this protein, and to determine 
if this truncation occurred in vivo.  We concluded that cathepsin B, a lysosomal protease, 
removed the C-terminal glycines of ubiquitin in vivo. The realization that desGG 
ubiquitin, or ubiquitin-t, is formed in vivo by cathepsin B was a unexpected and lead us 
to examine the localization of this protein across various tissues as well as explore its 
utility in differentiating another disease system with altered cathepsin B activity, cancer.  
This work as well as preliminary work towards understanding the origin and function of 
ubiquitin-t is presented in chapter IV of this thesis.  Chapter V provides conclusions as 
well as insights into where this research is headed. 
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CHAPTER II 
 
  PROTEIN MARKERS OF ANTIBIOTIC INDUCED NEPHROTOXICITY 
 
 
Introduction 
Aminoglycoside antibiotics are commonly used to treat gram negative bacterial 
infections.  Their use has been severely limited due to their propensity to damage the 
kidney.  The kidney consists of two major areas: cortex and medulla. It is through these 
areas that millions of nephrons, the functional unit of the kidney, traverse.  The cortex 
consists of the glomerulus, which has a 70KDa filter, as well as the proximal and distal 
tubules which function to concentrate and reabsorb the glomerular filtrate.  The medulla 
is comprised of the descending and ascending loop of Henley which functions to reabsorb 
water and Na+ respectively, as well as the collecting duct which is the last component of 
the nephron and functions to collect urine. Because of the kidney‟s role in filtering the 
blood, it is particularly susceptible to damage by antibiotics as well as other drugs.  
Though the drugs are known to accumulate in and damage proximal tubules, the specific 
mechanism responsible for this toxicity has remained elusive. 
 Though several mechanisms of toxicity have been postulated, a commonly 
accepted mechanism of toxicity by antibiotics is lysosomal injury [51].  Olbricht and 
colleagues microdissected out segments of the proximal tubule and analyzed lysosomal 
protease activity following gentamicin treatment.  They found that drug treatment 
actually led to a decrease in cathepsin B and L activity in the S1 and S2 segments [52].  
In fact, current biochemical methods to detect antibiotic induced nephrotoxicity exploit 
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this premise of lysosomal injury being the mechanism of toxicity by measuring the levels 
of N-acetyl glucosaminidase (NAG), a lysosomal enzyme [53-55].  Levels of γ-glutamyl 
transferase (GGT), a brush border enzyme, are also used to assess damage because both 
of these enzymes are excreted into the lumen of the tubules when damage occurs [56].  
These analyses are optimal for clinical settings since they involve non-invasive, urine 
analysis.  The problem with these assays is that there can be other causes for the change 
in enzyme activity [57]. There is also great intra- and inter-individual variation in urine 
volume and excretion of these enzymes [58].   
 Nephrotoxicity is also assessed histopathologically.  Once damage has occurred, 
the tissue morphology changes and is evident by swelling of the proximal tubules as well 
as large lysosomes [59].  Serum creatinine and Blood Urea Nitrogen (BUN) levels are 
used as indicators as well.  Creatinine is a protein produced by muscle therefore it is 
relatively stable so the clearance of this protein per minute can be used to assess kidney 
function.  BUN measures the amount of nitrogen that comes from urea, a waste product 
from the breaking down of proteins.  These assays are limited in that they are not very 
sensitive.  One will only see morphological, serum creatinine, and BUN changes after 
~2/3 of the nephron is damaged [2].  Ideally, one would want an early indicator of 
nephroxicity or at the very least a wider range of protein markers. 
 Recently, research efforts have been focused on this goal.  Though genes have 
been identified that are not only related to toxicity but could potentially be predictive of 
damage [60, 61], proteomics offers a unique opportunity to identify protein markers of 
nephrotoxocity and to indicate molecular processes involved in tissue damage.  
Charlwood et al. identified twenty proteins as markers of gentamicin nephroticity with 
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the use of 1D and 2D gels.  These proteins were either involved in the citric acid cycle, 
gluconeogenesis, fatty acid synthesis, or stress response [62].  A protein thought to be 
involved in the activation of complement was identified as a potential early marker of 
gentamicin nephrotoxicity [63].  Numerous other studies have started to use proteomics 
to obtain biomarkers of toxicity.  This topic is more thoroughly reviewed in [64].  More 
specifically, Meisterman et al. demonstrated the utility of direct tissue analysis by 
MALDI mass spectrometry for the identification of protein markers of gentamicin 
nephrotoxicity.  They identified transthyretin as a marker of damage and were also able 
to generate an image of this protein showing that it localized to the cortex of the kidney, 
the major site of damage [33].  The work presented in this chapter is a continuation of 
this project. 
MALDI mass spectrometry offers a valuable resource to not only identify protein 
markers of disease but to shed insight into mechanisms of drug toxicity.  By examining 
the differential expression of proteins between treated and untreated tissues, the extensive 
networks to which they belong can be elucidated in what is known as expression 
proteomics [65].  This approach builds upon the notion that once one knows which/how 
proteins change between disease states, a hypothesis can be drawn and tested through 
functional analyses to get back to the fundamental mechanisms of the disease. 
This work aimed to detect and characterize early protein markers of antibiotic 
induced nephrotoxicity through direct tissue profiling using MALDI MS.  This would 
provide a robust and high throughput method to detect toxicity in early leads. 
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Methods 
Animal studies.  All animal studies were performed at Roche Center for Medical 
Genomics at F. Hoffman-La Roche Ltd. in Basel Switzerland.  12 week old male Wistar 
rats (300g), five animals per group, were dosed subcutaneously with a single dose or once 
daily for 7 days as noted in the Table 1 with kanamycin (80 mg/kg or 400 mg/kg) or 
gentamicin (6.25 mg/kg, 25 mg/kg, or 100 mg/kg) (Sigma; dissolved in saline) or vehicle.  
Animals were sacrificed 24 hours after the last dose by CO2 inhalation. 
 
Sample Preparation.  Kidney samples were cut into 12 μm thick sagittal sections using 
a cryostat.  Serial sections were cut and stained with H&E for histology directed matrix 
deposition [40] and subsequently photographed.  On these images, ten virtual 200 μm 
spots were placed each in the cortex and medulla using Photoshop.  After overlaying 
these spots onto the optical image of the MALDI target plate, their coordinates were then 
transferred to an Automated Reagent Multispotter (Labcyte Inc., Sunnyvale, CA).  Using 
those coordinates, sections were spotted with sinapinic acid (20 mg/mL in 50:50 
acetonitrile: water, 0.1% TFA) after an ethanol wash (70%, 90%, 100% reagent grade) 
and seeding with a fine powder of sinapinic acid [38].   
 
Mass Spectrometry Analysis.  Samples were analyzed in duplicate. Spectra were 
collected on a Bruker AutoFlex mass spectrometer in linear mode equipped with a 
Smartbeam laser operated at 100Hz.   The spatial localization of the features was 
confirmed using imaging mass spectrometry at 250 μm resolution.  200 shots per spot 
were averaged for each spectrum in the profiling and imaging experiments.  Spectra were 
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preprocessed using ProTS Software (Biodesix, Inc) and images visualized using BioMap 
(Novartis). 
 
Statistical Analysis.  Twenty spectra from each area (cortex and medulla) for each 
animal were averaged after visual inspection of the data to ensure that all zero data were 
excluded.  The average spectra from each animal were generated into a feature table 
using ProTS Marker (Biodesix, Inc.).  A Significance Analysis of Microarrays (SAM) 
(Tuscher 2001)  was performed comparing control to low dose, low dose to high dose, 
and control to high dose for kanamycin and the same for gentamicin treated samples with 
the addition of a mid dose comparison at 24 hours and 8 days.  For this study features that 
were found significant with a fewer than 10% false discovery rate were recorded.   
 
Protein Identification.  Tissue samples were homogenized by manual mincing with 
Tissue Protein Extraction Reagent (T-PER) extraction buffer (Pierce) according to 
manufacturers recommendation while on ice.  Extracts were briefly sonicated with an 
electronic emulsifier (Branson Sonifier).  Samples were then centrifuged for 5 min at 
10,000xg and the supernatant collected and used for all further analysis. 
Proteins were then identified by one of three ways as described in the chart 
(Figure 5).  The tissue homogenate was separated on a Vydac C4 column by HPLC using 
a linear acetonitrile gradient from 2-95%.  Fractions (0.5ml) were collected in a 96-well 
plate and then vacuumed to dryness in a Speedvac.  Samples were resuspended in 20 μl 
40% ACN/0.1% TFA and spotted on a MALDI target to identify the fraction of interest.  
Once that fraction was determined, the sample was 1) subjected to an in solution digest 
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with trypsin (Promega) or LysC (Fisher),  dried down and then resuspended in 2% 
ACN/0.1% FA followed by MS/MS analysis on a Bruker UltraFlex or LCQ or 2) 
subjected further separated on a 10-20% Tricine Gel (Novex).   The corresponding band 
was cut and digested with the aforementioned enzymes.  Peptides were extracted with 
60% ACN/0.1% formic acid (FA), dried down and resuspended in 2% ACN/0.1% FA, 
and then subjected to MS/MS analysis on the Bruker UltraFlex or LCQ.  3)  The tissue 
homogenate was run on a Tricine gel and the band of interest excised and digested with 
an enzyme followed by the previously described workflow.   
ESI generated spectra were submitted to the TransProteomic Pipeline where they 
were searched against a SwissProt rat International Protein database.  TOF-TOF spectra 
were processed with Flex Analysis (Bruker) and submitted to MASCOT where they were 
searched against the Swiss Prot database. 
 
Identification of truncated ubiquitin.  Rat kidney cortex homogenates were subjected 
to GluC digestion.  First, homogenates were separated on a C4 RP column by HPLC into 
a 96 well plate and vacuumed to dryness using a SpeedVac.  Samples were reconstituted 
in 20 μl 40%ACN:water 0.1% TFA and manually spotted onto a MALDI target where 
they were mixed 1:1 with SA.  The fraction containing m/z 8451 was determined by 
MALDI-TOF, dried down and resuspended in 25 μl of 100mM ammonium bicarbonate.  
The sample was reduced with 50mM DTT and alkylated with iotaacetamide.  GluC (2 ul 
of 1 μg/μl) and digest at 37oC for 16 hrs.  The reaction was stopped with 0.1% formic 
acid (FA).  The sample was vacuumed to dryness again and resuspended in 25 μl 
0.1%FA.  MS/MS analysis was performed on a Thermo LTQ linear ion trap, and the 
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resulting MS and MS/MS data searched against an International Protein Index (IPI) rat 
database using SEQUEST.   
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Table 1.  Outline of drug dosing. 
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Figure 5.  Protein ID Schematic.  Tissue is mechanically homogenized and separated 
using reverse phase HPLC.  Fraction of interest is determined by MALDI MS and either 
1) subjected to an in-solution digest or 2) further separated on a 1D gel where an in-gel 
digest is performed.  Alternatively, the tissue homogenate is 3) separated on a 1D gel, 
band of interest excised and digested.  All peptides were sequenced using MS/MS 
analysis and searched against a database. 
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Results and Discussion 
The use of aminoglycosides such as gentamicin and kanamycin in treatment 
against gram negative bacterial infections has been greatly limited due to their propensity 
for damage to the kidney.  To provide additional markers for this damage, animals were 
given a low or non-toxic dose of the drugs as well as a high toxic dose to evaluate the 
proteomic differences between the doses.  As reported, treatment with these drugs results 
in damage to the proximal tubules [66] as is evident in the H&E stained slide (Figure 6). 
Direct tissue profiling revealed vast changes in the proteome in response to 
gentamicin and kanamycin treatment with the most drastic changes occurring in the 
cortex of the chronic dosed animals (Figures 7 and 8).  Since these drugs are cortical 
toxicants, these data are in agreement with the known localization of damage for these 
xenobiotics.  The finding that there are proteomic changes in the medulla, as evident by 
the differences in intensity of several features as a result of drug treatment (Figures 7 
and 8) is surprising since the drugs are thought to primarily damage the cortex. These 
data suggest a more comprehensive interplay between the drugs and the kidney.  The data 
illustrates the effect of duration and concentration of the drugs on the kidney proteome.  
The longer and higher the dose of both drugs, the greater the observed effect on features 
observed in the MALDI spectra. 
The first objective of the study was to identify early markers of toxicity.  For this 
purpose, an early marker was defined as a feature that exhibited significant changes as 
early as 24hrs after a low dose of either kanamycin or gentamicin.  Using these 
guidelines, one protein, lysozyme, was identified as an early marker of kanamycin 
toxicity (Figure 9).  This protein is a lysosomal protease that was originally used as a 
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urinary marker of proximal tubule damage but it was found to lack the sensitivity needed 
to reliably diagnosis damage making it unsuitable for analysis [67-69].  Lysozyme was 
not determined as an early marker of gentamicin toxicity, though it was identified as 
showing differential expression as a result of chronic gentamicin treatment.  These results 
suggest that lysozyme could be a viable marker for kanamycin toxicity in situ.  Using the 
aforementioned constraints, analysis of gentamicin treated samples did not lead to the 
discovery of any early markers.   
Though the initial aim of the study was to determine early markers of toxicity, 
proteins that exhibited differential expression as a result of maximum dosage or chronic 
drug treatment were investigated.  These features were termed “general markers” of 
toxicity and the results from are illustrated in Tables 2-7.  An important observation to 
note is the abundance of features that are decreased in the cortex of chronic dosed 
animals.  This underscores the biological and morphological changes in the tissue.  
Interestingly, we did detect significant changes in features in the medulla as a result of 
drug treatment.  One feature m/z 4508 was decreased as a result of a single mid-dose of 
gentamicin whereas 17 features were decreased as a result of an eight day regiment of 
gentamicin treatment (Table 4).  These features included m/z 8039, 9977, 3477, 15202, 
15411, 16155, 5484, 7576, 3432, 7598, 9937, 7700, 8253, 9717, 12436, 7931, and 8364.  
Three features, m/z 7616, 15197, and 15153 were significantly increased after a single 
high dose of kanamycin when compared to a lower mid-dose (Table 7).  Two features 
m/z 6104 and 8450 were significantly decreased after a chronic high dose of kanamycin 
compared to control animals (Table 7).  This finding suggests that although these drugs 
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exert their primary damage on the cortex, there are some secondary effects in the 
medulla.  
There were several features that were differentially expressed 24 hr post a high 
dose of both gentamicin and kanamycin that corresponded to changes observed after a 
chronic 8 day dosing.  Eight features from the gentamicin study were identified that fit 
this criterion.  They were m/z 17583, 8450, 6030, 4988, 8040, 9978, 15826, and 8927 
(Tables 2 and 3).  Six features from the kanamycin study were identified that fit this 
criterion.  They were m/z 14853, 8791, 17389, 12563, 8040, and 7842 (Tables 5 and 6). 
Only one feature, m/z 17583, displayed a consistent significant decrease with a 
lower dose of gentamicin as compared to the high dose at 24hr (Table 2).  In a 
comparison of 8 day dosed samples 22 features displayed a consistent significant 
decrease across all doses of gentamicin (Table 3).  They were m/z 12344, 5485, 5903, 
6030, 8040, 9665, 8365, 12132, 9978, 14005, 6663, 8123, 6178, 8450, 10260, 15828, 
10812, 15202, 9326, 4923, 7576 and 7598. 
Performing a corresponding analysis with the kanamycin treated samples 
demonstrated two features in common between the comparison of control to low dose 
and control to high dose samples at 24 hrs post dose: m/z 14853 and 7444 (Table 5).  But 
a comparison between low dose to high dose and control to high dose samples yielded 
seven features in common (m/z 12563, 7922, 7929, 15855, 5904, 8040, and 10280) 
(Table 5).  Comparing features identified as significant in the 8 day chronic dosed gave 
similar results.  Though no features were common between all of the doses, 47 features 
were in common between a comparison between low dose to high dose and control to 
high dose.  These were m/z 12957, 14853, 17323, 3832, 17263, 17388, 8659, 8791, 
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17582, 8848, 10201, 6030, 5406, 10183, 6867, 12294, 4989, 6049, 4463, 8040, 12131, 
8927, 4182, 10143, 10495, 4225, 7106, 8365, 8450, 6104, 10365, 14212, 8123, 5485, 
7883, 6178, 13468, 5466, 6648, 7043, 9717, 9665, 4924, 14085, 10260, 12345, and 9938 
(Table 6).  These results suggest that the features in common could potentially be useful 
diagnosis tools due to their appearance at lower doses. 
From this study twelve proteins were identified from the list of statistically 
significant features indicative of nephrotoxicity by methods previously described (Table 
8).  Eight of these proteins were found significant in both the gentamicin and kanamycin 
studies.  Two of these proteins were increased in the cortex of drug treated samples, 
transthyretin and lysozyme (Figure 10).  Lysozyme was discussed earlier in this chapter.  
Transthyretin, or prealbumin has been used as a marker of nutritional stress [70-72] and 
breast cancer [73]. It was recently identified as a marker of gentamicin nephrotoxicity 
[33].  This work extends this identification to kanamycin nephrotoxicity as well.  
Interestingly, lysozyme and transthyretin (TTR) are both ligands of the megalin receptor 
[74, 75].  Megalin is also the receptor for the aminoglycosides gentamicin and kanamycin 
[76, 77].  These data suggest that these drugs preferentially bind to megalin, thereby 
preventing uptake and release of lysozyme and TTR into the bloodstream [33].  
Additionally, three of the other proteins identified as markers of nephrotoxicity, 
cytochrome C, and hemoglobin α and β are also ligands of the megalin receptor [74, 78].  
This work supports the hypothesis that treatment with a megalin antagonist would 
alleviate antibiotic induced nephrotoxicity.  Recently, cytochrome C was demonstrated to 
inhibit gentamicin accumulation in the kidney cortex consequently preventing damage 
[79].   A more detailed description of megalin can be found in the fourth chapter. 
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Eight proteins were identified as having a statically significant decrease in the 
cortex of drug treated samples (Figure 11).  Two of these are involved in energy 
production- ATP synthase coupling factor 6 and ATP synthase subunit epsilon.  ATP 
synthase is a mitochondrial enzyme that is composed of two units [80].  The first unit, F1, 
is the catalytic unit and is comprised of five other subunits, one of which is subunit 
epsilon.  ATP synthase coupling factor 6 is associated with the second unit F0, the energy 
transduction unit. The identification of ATP synthase subunit epsilon and coupling factor 
6 as being decreased in response to drug treatment points towards the role of 
mitochondrial injury in nephrotoxicity.  Investigators have shown that gentamicin impairs 
cellular energy production and inhibits mitochondrial phosphorylation [81, 82].   
Two other proteins, cytochrome C and cytochrome C oxidase polypeptide Va are 
integral in apoptosis.  Cytochrome C is released from mitochondria in response to pro-
apoptotic stimuli.  A decrease in these proteins points not only points to an impaired 
apoptotic mechanism which could potentially protect the kidney from damage, but this 
too suggests a role of mitochondrial injury in nephrotoxicity. 
Macrophage inhibitory factor (MIF), a protein involved in regulating immunity 
was also decreased.  Though MIF is constituitively expressed, it has been shown that MIF 
is increased in kidney diseases such as experimental and human glomerulonephritis and 
kidney transplant rejection [83-85].  We would expect that MIF would be increased with 
damage to the kidney.  It was surprising to discover a decrease in this protein as a result 
of drug treatment.  It is possible that aminoglycosides inhibit the release of MIF.   
Hemoglobin α 1/2 and β were decreased as well.  These proteins are involved in 
oxygen transport and lend credence to the role of oxidation in nephrotoxicity [86, 87]. 
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Hemoglobin was recently identified as a urinary marker of nephrotoxicity [88].  It would 
follow that a decrease of hemoglobin in tissue is indicative of an increase in urine.   
 Our analysis resulted in the discovery of a C-terminal desGG ubiquitin.  The 
formation of this protein is tryptic in nature, therefore trypsin was not used to digest the 
protein for identification.  An alternate enzyme, Glu-C, was used to verify the sequence 
of Ub-t.  The analysis yielded the confident ID of the C-terminal des-GG peptide of 
ubiquitin with an Xcorr=4.24 and 30/88 ions matched (Figure 12).  Despite this strong 
SEQUEST score, the algorithm did not identify the base peak of the spectrum, m/z 
872.04 nor the next most intense peak m/z 992.43.  However, this provided  further 
confidence in the identification after manual inspection revealed these ions would 
account for the  y22
+3
 and y16
+2
 fragment ions, respectively, which represent expected 
predominant cleavages due to the presence of aspartic acid and the sequestration of the 
mobile protons by basic arginine residues .  To be more specific, the SEQUEST 
algorithm does not account for enhanced cleavage at specific amino acid residues such as 
aspartic acid, as observed in the Fig. 12.  These cleavages are in agreement with the 
predicted cleavage sites as determined by the mobile proton model which states that 
peptide fragmentation requires a proton at the cleavage site.  If that proton is sequestered, 
or bound by a basic amino acid side-chain, then energy will be required to mobilize that 
proton to the peptide backbone to induce fragmentation [89].  In the peptide of interest, 
cleavage at the aspartic acid residues is preferred because the mobile proton(s) are being 
sequestered by the arginine residues, thereby allowing the acidic side chain of aspartic 
acid to initiate cleavage.  It has been established in the literature that this enhanced 
cleavage occurs only if the number of protons added to the peptide is less than or equal to 
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the number of arginines present [90].  This correlates well with the presence of two 
arginines in the y16
+2
 peptide and three arginines in the y22
+3
 peptide (Figure 12). 
Interestingly we found that desGG ubiquitin (Ub-t) was decreased in the cortex of 
drug treated samples (Figure 13).  This was intriguing since it has been demonstrated 
that the C-terminal glycines are necessary for activation of ubiquitin and subsequent 
protein degradation [50].   Oxidatively modified proteins are degraded by the ubiquitin 
proteosome system.  The  observation that Ub-t, or inactive ubiquitin is decreased with 
drug treatment suggests the cells‟ role in combating oxidative damage due to the drugs 
[86, 87].  The finding that there was a modified form of ubiquitin was quite intriguing 
and one in which we decided to further explore.  This work will be discussed in 
subsequent chapters. 
 In summary, we have used direct tissue MALDI MS to detect protein markers of 
antibiotic induced nephrotoxicity.  One protein, lysozyme, was identified as an early 
marker of damage using the guidelines that a significant change was observed as early as 
24 hours following a non-toxic dose.  Adjusting the definition of an early marker to a 
feature that exhibits statistically significant changes as early as 24 hours post a toxic dose 
yielded eight features from the gentamicin treated samples and six from the kanamycin 
treated samples.  Twenty two features were identified as general markers of gentamicin 
damage due to their statistical changes after 8 days of a toxic dose of the drug.  Twenty-
three features were identified as general markers of kanamycin damage due to their 
stastical changes after 8 days of a toxic dose of the drug.  Ten proteins were identified as 
markers for both gentamicin and kanamycin damage.  Among those identified were 
proteins that suggest the role of megalin, mitochondrial and lysosomal injury, as well as 
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oxidation in mediating toxicity.  Interestingly a truncated form of ubiquitin was identified 
as a cortical marker of damage.  This novel finding will be further explored in the next 
chapter.  Taken together this work demonstrates the utility of direct tissue MALDI MS in 
detecting early markers of antibiotic induced nephrotoxicity.  This data not only 
potentially supplements the known protein markers but can possibly shed insight into the 
mechanism of toxicity. 
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Figure 6.  Histopathological analysis of gentamicin and kanamycin treated kidneys.  
Samples from control (A and C), 8 day 400 mg/kg kanamycin (B) and 100 mg/kg 
gentamicin treated samples.  Proximal tubules are disrupted and cells are enlarged as 
indicated by arrows in drug treated samples.  Scale bar=100μm  
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Figure 9.  Lysozyme as an early marker of kanamycin toxicity.  Average spectra from 
control, low and high dose animals after 24hrs and 8 days of kanamycin treatment.  
Intensity of peak at m/z 14860 shows a steady increase even after 24hrs with standard 
error in inset. 
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Table 2.  Top differentially expressed features as determined by SAM comparing 
cortex of 24hr gentamicin treated tissue.  Data is presented with respect to higher 
dosed tissue: black-up, red-down (ex. Control vs. low dose- Up in low dose/down in low 
dose).  FDR <10%.  N/A indicates there were no features identified that met the indicated 
criteria.  LD-low dose; MD-mid dose; HD-high dose.  Values listed in order of 
decreasing SAM score. 
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Table 4.  Top differentially expressed features as determined by SAM comparing 
medulla of A) 24hr and B) 8 day gentamicin treated tissue.  Data is presented with 
respect to higher dosed tissue: black-up, red-down (ex. Control vs. low dose- Up in low 
dose/down in low dose).  FDR <10%.  N/A indicates there were no features identified 
that met the indicated criteria.  LD-low dose;  MD-mid dose; HD-high dose.  Values 
listed in order of decreasing SAM score. 
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Table 7.  Top differentially expressed features as determined by SAM comparing 
medulla of  A) 24 hr and B) 8 day kanamycin treated tissue.  Data is presented with 
respect to higher dosed tissue: black-up, red-down (ex. Control vs. low dose- Up in low 
dose/down in low dose).  FDR <10%.  N/A indicates there were no features identified 
that met the indicated criteria.  LD-low dose; HD-high dose.  Values listed in order of 
decreasing SAM score. 
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Table 8.  Markers identified from gentamicin and kanamycin studies.  Proteins were 
found to be significantly increased (1
st
 two listed) or decreased (others listed) after 8 days 
of gentamicin and kanamycin treatment except where noted.  TPP- Transproteomic 
Pipeline; Gent.-protein found in gentamicin study; Kana.-protein found in kanamycin 
study; #- marker after 24hrs; *-protein identified previously in lab; ^-protein identified as 
described in text 
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Figure 10.  Images of proteins increased in the cortex with drug treatment.  Images 
shown are kidneys from 8 day control and high dosed gentamicin and kanamycin treated 
animals.  The localization of the indicated proteins is visualized as a heat map.  Images 
acquired at 250 µm resolution. 
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Figure 11.  Images of proteins decreased in cortex with drug treatment.  Images 
shown are kidneys from 8 day control and high dosed gentamicin and kanamycin treated 
animals.  The localization of the indicated proteins is visualized as a heat map.  Images 
acquired at 250 µm resolution.   
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Figure 13.  Localization of truncated ubiquitin as a result of antibiotic treatment.  
Images shown are kidneys from 8 day control and high dosed gentamicin and kanamycin 
treated animals.  Localization of protein is visualized as a heat map.  Images acquired at 
250 µm resolution. 
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CHAPTER III 
 
 UBIQUITIN DISCOVERY AND FUNCTION  
 
Overview 
This chapter will chronicle the original discovery of ubiquitin from bovine thymus as a 
74 amino acid protein and then its subsequent acceptance as a 76 amino acid protein 
involved in protein degradation.  This chapter will provide the backdrop for the inquiry 
into the validation of in vivo expression of ubiquitin-t. 
 
Ubiquitin Discovery  
In 2004, the nobel prize for chemistry was awarded to Aaron Ciechanover, Avram 
Hershko, and Irwin Rose for the discovery of ubiquitin and the ubiquitin proteasome 
system.  This discovery revolutionized the view the scientific community held with 
regards to intracellular proteolysis.  It was originally proposed that protein degradation 
was mostly lysosomal, but several pieces of data started to suggest otherwise.  
Researchers could not explain the ATP requirement, varying half-lives of several 
proteins, nor insensitivity to several lysosomal inhibitors [91] involved in protein 
degradation.  Then in 1977, the first cell-free proteolytic prep was obtained from rabbit 
reticulocytes [92].  This was pivotal because this extract was free of lysosomes yet still 
was able to degrade hemoglobin with the addition of ATP.  Soon thereafter, Ciechanover 
and colleagues fractionated the reticulocyte crude extract into two fractions.  It was in the 
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first fraction that the active component was purified and identified to be an 8.5kDa 
protein then termed ATP-dependent Proteolysis Factor 1, or APF-1 [93]. 
Concomitantly, a  74 amino acid protein of unknown function was purified during 
the isolation of thymopoeitin that had protein degradation activity [94].  It was found to 
be expressed in all cells and appeared to be involved in the immune response [95, 96].  
Though this was later found to be incorrect [97], it was named ubiquitous immunopoietic 
polypeptide (UBIP) [95].   
Soon thereafter, investigators began to suspect that APF-1 and ubiquitin were the 
same protein.  Ciechanover et al. characterized APF-1 from reticulocytes and found that 
it had the same molecular weight as well as amino acid composition as ubiquitin[98].  In 
1980 Wilkinson et al. demonstrated that ubiquitin was APF-1 [99]. 
At this point ubiquitin, a heat stable protein with an energy requirement for 
protein degradation, was accepted to be a 74 amino acid protein ending in arginine [96].  
Then conflicting reports on the both the structure and activity of ubiquitin started to arise.  
Researchers were finding that some preparations of ubiquitin were unable to trigger 
proteolysis [99].  Sequencing of these samples led to the discovery that in some cases a 
short glyclglycine tag was attached to the end of ubiquitin [100].  This led to confusion as 
to the actual structure of the protein in question.  It was known that the C-terminal 
glycines were necessary for protein degradation [100] but it was not clear as to the origin 
of the dipeptide.  To complicate matters, Wilkinson found that not only did the samples 
with inactive ubiquitin have a completely different species in them as determined by 
HPLC but, that active ubiquitin could be converted to an inactive form with trypsin.  
Then in 1985, Arthur Haas and his colleagues made the discovery that ubiquitin actually 
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has 76 amino acids, including a C-terminal diglycine tail, that can be cleaved by an 
unnamed lysosomal protease [50].  This protease with trypsin-like specificity, but 
presumably a cathepsin-like enzyme because of its molecular weight and specificity, can 
become activated at acidic pH and released during homogenization, thereby cleaving the 
C-terminal glycine residues and effectively inactivating the protein.  It was Haas‟ 
recommendation, and the accepted view in the field that this cleavage was an artifact of 
sample handling and that only the full 76 AA protein should be referred to as ubiquitin.  
The 74 amino acid cleavage product should be referred to as ubiquitin-t for truncated. 
 
Ubiquitin Activity 
The ubiquitination process is one that has been heavily studied and characterized. 
We now know that an E1 activating enzyme covalently attaches to Gly
76
 of ubiquitin, 
then ubiquitin is transferred to an E2 conjugating enzyme through a thioester bond, and 
finally an E3 ligase covalently attaches it to lysine residues in the target protein for 
degradation [101, 102].  Four or more ubiquitin moieties attached to Lys
48
 of ubiquitin 
signal for a target protein to be degraded by the proteosome [103].  The proteosome is a 
large protease consisting of a 20S catalytic core of four stacked rings where 
polyubiquitinated proteins are digested into peptides in a caspase, trypsin, and 
chymotrypsin-like manner [104].  The proteosome also has a 19S regulatory subunit that 
functions to recognize and allow polyubiquitinated proteins into the catalytic subunit 
[105, 106].  Important to note is that the proteasome releases free ubiquitin with the aid of 
deubiquitinases that recognize and cleave the isopeptide bond between Gly
76 
of ubiquitin 
53 
 
and the ε-NH2 group of lysine on the target protein.  In this sense, ubiquitination is a 
reversible post-translational modification, allowing for the recycling of free ubiquitin. 
But, ubiquitination does not only signal proteosomal protein degradation.  There 
are several alternative processes triggered by ubiquitin attachment.  The various functions 
of ubiquitin modification are outlined in Figure 14.  There is evidence that polyubiquitin 
chains constructed through Lys
63
 of ubiquitin are involved in activation of transcription 
factors [107] and could play a key role in regulating transcription as reviewed in 
Conaway et al [108].  It is now known that mono- and diubiquitination are involved in 
protein trafficking through receptor mediated endocytosis [109].  In this process, 
ubiquitinated membrane proteins are internalized, taken into early endosomes, and 
transported to multivesicular bodies which are then fused to lysosomes for degradation.   
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Figure 14.  Schematic of the various functions of ubiquitin.  A) Ub activation, 
conjugation and ligation to a target protein for degradation in the proteasome.  B) 
Ubiquitin mediated endocytosis and trafficking of membrane proteins to the lysosome.  
C) Monoubiquitination targeting proteins to nuclear foci leading to signaling.  D) 
Ubiquitin like proteins such as SUMO target proteins to the nuclear pore complex.  E) 
Polyubiquitin through Lys63 leading to activation of transcription.  Reprinted with 
permission from Macmillan Publishers Ltd: [91]
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Lysosomal Proteolysis 
 
 The lysosome is an intracellular membranous organelle that contains various 
proteases that function optimally at an acidic pH.  Proteins are targeted to the lysosome 
through receptor mediated endocytosis, pinocytosis, phagocytosis, and autophagy as 
described in Figure 15 where they are cleaved by lysosomal cathepsins.  Cathepsins can 
be divided into three groups: cysteine, the largest and best known, aspartic and serine 
hydrolases.  There are 11 human cysteine cathepsins B, C, F, H, L, K, O, S, V, W, and X.  
Cathepsin D and E are aspartic hydrolase and cathepsins A and G are serine hydrolases. 
Most of these enzymes behave as endoproteinases with the exception of cathepsin B 
which can act as both an endo and exoproteinase [110].  A more detailed description of 
cathepsin B can be found in chapter IV.  Though cathepsins exert most of their activity 
primarily in the lysosome, they can be secreted and act to digest extracellular proteins 
and membranes, something that has proved key in cancer progression [111-113]. 
 Ubiquitin has a key role in two of the lysosomal trafficking mechanisms: receptor 
mediated endocytosis, discussed previously and autophagy.  Autophagy is the process by 
which a cell degrades its own organelles.  In this process a membrane termed an 
autophagic vacuole, surrounds ubiquitinated proteins and shuttles them to the late 
endosome and subsequently, the lysosome [114]. 
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Figure 15.  Schematic of the four proteolytic processes mediated by the lysosome.  1) 
Specific receptor-mediated endocytosis.  2) Pinocytosis (nonspecific engulfment of 
proteins in extracellular fluid 3) Phagocytosis (engulfment of extracellular particles) and 
4) Autophagy (micro- and macro-; of intracellular proteins and organelles).  Reprinted  
with permission from Macmillan Publishers Ltd: [91]  
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CHAPTER IV 
 
CHARACTERIZATION OF UBIQUITIN-T 
 
Overview 
Using MALDI imaging mass spectrometry, this chapter presents the finding that 
ubiquitin-t naturally occurs in kidney and that this cleavage is not a sample handling 
artifact but is created by cathepsin B in vivo.  Additional work examining the presence of 
this protein in other diseased and normal tissue populations will be presented as well as 
preliminary results aimed at determining the origin and function of this protein. 
 
Ubiquitin-t 
In our analysis of early markers of drug induced kidney toxicity, we discovered 
that a C-terminal truncated form of ubiquitin (ub-t) was reduced with drug treatment.  
Recently, several researchers have reported the presence of this cleaved ubiquitin in silico 
[115] and in situ [33].  These investigators found the ub-t form of ubiquitin as a kidney 
cortex marker by direct tissue experiments using MALDI mass spectrometry.  Similarly, 
Goncalves et al. identified this cleavage product as a potential biomarker for breast 
cancer in human breast cancer cells by surface enhanced laser desorption ionization MS.  
Neither study focused on investigating the origin of the truncated ubiquitin although the 
latter suggested that the truncation was a result of trypsin cleavage due to increased 
ubiquitination [115].  The authors also suggested that the truncation was not an artifact of 
their analysis due to their use of protease inhibitors in their homogenization procedure 
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[115]. Nonetheless, it needs to be conclusively shown that this form of the protein is not 
an artifact of the experimental protocol.  
 
Methods 
Localization of cleaved ubiquitin in kidney.  Frozen rat kidney was sectioned at 12 μm 
thickness on a cryostat and thaw mounted onto a gold-coated MALDI target.  Samples 
were allowed to dry in a vacuum dessicator and washed with a series of reagent grade 
ethanol washes (70%, 90%, 100%).  Sinapinic acid (SA) matrix was applied (20 mg/ml 
50:50 ACN:water 0.1% TFA) using a TLC nebulizer (25 mg/ml 50:50 ACN:water 0.1% 
TFA).  Samples were analyzed on a Bruker AutoFlex II mass spectrometer using a 
smartbeam laser in linear mode.  Images were reconstructed using FlexImaging Software 
(Bruker Daltonics). 
 
Ubiquitin In Situ Cleavage.  Mammalian ubiquitin (Ub) (1 mg) (Boston BioChem) was 
dissolved in 1 ml 0.1M ammonium acetate buffer with 1mM EDTA and DTT pH 5.4 
[116].  Fresh frozen rat kidneys were sectioned in a cryostat at 12 μm thickness and thaw 
mounted onto gold coated MALDI targets.  Samples were allowed to dry in a vacuum 
dessicator for atleast 30 minutes and were spotted with or without cathepsin B& L 
inhibitor (10 μl and 5 μl respectively) (Biovision, Inc.) in a 250 μm array using the 
Portrait 630 (Labcyte)  followed by application of 20 mg/ml sinapinic acid matrix (SA). 
 
Ubiquitin In Vitro Cleavage.  Cathepsin B, D, and L (Sigma) and carboxypeptidase Y 
(Sigma) were added to 250 μl of 1 mg/ml ubiquitin in ammonium acetate buffer (100mM 
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with 1mM EDTA and DTT pH 5.4) according to manufacturer‟s guidelines.  In brief 12.5 
μl cathepsin B, 25 μl cathepsin D, 5 μl cathepsin L, and 100 μl carboxypeptidase Y were 
added.  The solution was incubated at 37
o
C with aliquots taken out after 5, 10, 20, 30, and 
60 minutes and overnight.  The reaction was stopped by adding acetonitrile (ACN) 1:1 
(v/v).  The reaction solution (250 nl) was deposited manually on a gold coated MALDI 
target followed by manual deposition of 250 nl 20 mg/ml SA. 
 
In Situ inhibition Studies.  Cold inhibition experiment. Frozen rat tissue sectioned as 
above and placed on a gold-coated MALDI target.  Cathepsin B inhibitor (1 μl) 
(Biovision,Inc.) was spotted onto the tissue in the kidney cortex at -15
o
C after having the 
vial on ice for ~30minutes.  The tissue section was then thaw-mounted and placed in a 
vacuum desiccator for at least ~30minutes.  SA (250 nl of 20 mg/ml) was manually 
deposited directly on top of the inhibitor spots.  Once dried another manual deposit of 
matrix was applied and spots analyzed using a Bruker Autoflex. 
 
Inhibition tissue overlay studies.  Multiple spots of ubiquitin (500nl 1mg/ml in acetate 
buffer prepared as previously described) with or without cathepsin B inhibitor (premixed 
10 μl ubiquitin and 1 μl inhibitor) were manually deposited onto a MALDI target plate 
and allowed to dry.  Rat kidney tissue sectioned as described was placed on top of the 
dried spots and thaw mounted.  Samples were placed in a vacuum dessicator and allowed 
to dry.  SA was applied as described above and spots analyzed using a Bruker Autoflex. 
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Desiccation time course study.  Rat kidney tissue was sectioned and thaw mounted as 
described before and placed in a vacuum desiccator.  Samples were taken out and given 
an ethanol rinse as described after 5, 10, 15, 20, 30, 60 and 120 min in the desiccator as 
well as overnight.  Two sections were cut for each time point.  Five spots of SA were 
manually deposited in the kidney cortex as described on each tissue.  Spectra acquired as 
above and averaged for each animal. 
 
In vivo Cathepsin B inhibition.  Male Fischer 344 rats from Charles River Laboratories 
(Wilmington, MA) were dosed i.p. with 5 mg (5X1mg/ml in saline and dimethylsulfate 
every 6 hrs) L-3-trans-(Propylcarbamyl) oxirane-2-carbonyl)-L-isoleucyl-L-proline 
methyl ester (CA074ME) or empty vector (saline and DMSO) in accordance to animal 
protocol M/08/059.  Animals were sacrificed 6 hrs post dose and their kidneys excised 
and immediately frozen and stored at -80
o
C until analysis.  Tissue was then sectioned, 
thaw mounted, and analyzed as described above. 
 
Cathepsin B (CATB) and L (CATL) Activity Assay.  Kidney homogenates from 
control and CA074Me treated animals as well as gentamicin and kanamycin treated 
animals were assayed for cathepsin B and L activity following manufacturer‟s protocol 
(Biovision) using the substrates‟ Ac-RR-AFC and Ac-FR-AFC respectively.  In brief 200 
µg of the tissue homogenate were incubated with 50 µl of the respective reaction buffer 
and 2 µl of the appropriate substrate for 2 hours at 37
o
C. 
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Spectral Processing.  All spectra were externally calibrated and then baselined, 
normalized and aligned using ProTS Data (BioDesix, Inc) software.  Images were 
visualized and normalized  using Flex Analysis (Bruker Daltonics). 
 
Diglycine Addition Experiment.  
13
C labeled diglycine was synthesized by Junhai 
Yang.    A 1.2 mg/ml solution of 
13
C labeled diglycine was added to 1 mg/ml ubiquitin in 
activating acetate buffer and cathepsin B (Sigma) in the presence of a cell free rabbit 
reticulocyte extract (Boston BioChem) with excess ATP.  The mixture was incubated at 
37
o
C overnight.  The solution of 
13
C labeled diglycine was also manually deposited onto 
rat kidney tissue with 1 mg/ml ubiquitin and excess ATP.  SA was manually deposited on 
the tissue to analyze by MALDI. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
Ubiquitin Endocytosis Experiments.  Cell culture. L2-RYC rat yolk sac embryonic 
carcinoma cells (American Type Culture Collection, Manassas, VA) were cultured as 
described in Dulbecco‟s Modified Medium containing 10% fetal calf serum [117].   
 
Cellular uptake of ubiquitin.  Cells were grown for 3 days on 6 cover slips in serum free 
media.  Alexa488-conjugated ubiquitin was synthesized by Junhai Yang according to 
manufacturers protocol (Molecular Probes) and filtered using a G-25 PD-10 column to 
remove low molecular weight contaminating free probe. Fluorescent ubiquitin (30µl of 
1mg/ml) was added to the media with and without a megalin blocking antibody 
previously described [118] (gift from Pierre Verrhoust), receptor associated protein (30µl 
of 2.5 mg/ml) (Molecular Innovations, Novi, MI), and gentamicin (100µl of 50 mg/ml) 
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(CellGro).  After 5 hr incubation, cells were washed twice with 1X PBS and then fixed 
for 15 minutes in 4% formaldehyde/1X PBS.  Uptake was visualized using a Leica 
confocal microscope. 
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Results and Discussion 
Several researchers have reported the presence of desGG ubiquitin (Ub-t) in 
kidney [33] and breast tumor cell lines and tissue [115].  The source of this cleavage was 
not addressed.  The observation that Ub-t was a marker of antibiotic-induced 
nephrotoxicity led us to investigate if this cleavage occurs in vivo.    
 
Localization of ubiquitin-t in kidney.   
The localization of ubiquitin-t in kidney was determined with imaging mass 
spectrometry.  A two dimensional ion map was constructed using m/z 8451 (Figure 16).  
Ub-t can be seen in the kidney cortex whereas full length ubiquitin is found primarily in 
the medulla. 
 
In situ and in vitro ubiquitin cleavage 
The regionalized localization of Ub-t in these samples suggested that this protein 
is a natural metabolite and is not an artifact.  The first objective was to recapitulate the 
cleavage directly on tissue.  Ubiquitin standard (in an acidic buffer) was spotted onto 
unwashed kidney tissue to facilitate cleavage by a lysosomal protease.  Mass 
spectrometry analysis revealed a peak at m/z 8451 corresponding to the removal of the C-
terminal glycines from ubiquitin in the kidney cortex, the outermost layer of the kidney 
(data not shown).  Using this information, a 250 μm array containing ubiquitin in the 
activating buffer was printed on the tissue spanning across the cortex and medulla.  
Figure 17a (top panel) shows the resulting image indicating presence of the cleaved 
ubiquitin in the cortex.  In vitro experiments using various proteases and ubiquitin 
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standard revealed complete conversion of full length to cleaved ubiquitin as early as 5 
minutes with cathepsin B as seen by presence of a peak at m/z 8451 (Fig 18).  Though all 
the proteases tested cleaved the Gly-gly from Ub, cathepsin B was found to be the most 
effective protease using the conditions outlined in the experiment.  As a result, a 
cathepsin B inhibitor was chosen to use for on-tissue inhibition studies.  Figure 17b 
(bottom panel) shows that addition of the inhibitor did in fact prevent cleavage of 
ubiquitin as evident by lack of a signal at m/z 8451. 
 From this work it was determined that the in situ cleavage of exogenous ubiquitin 
does not occur after the tissue is washed, presumably because of inactivation of the 
enzyme responsible.  If this were an artifact it would have to occur before this step.  The 
tissue is sectioned at below zero temperatures which significantly retard enzyme activity.  
If this was an artifact of the sample preparation then it would have to occur upon thaw 
mounting and/or in the vacuum desiccator.   
 
Effect of experimental protocol on Ub-t 
To evaluate if cleavage of ubiquitin occurs upon thaw mounting the tissue on the 
MALDI plate, a cathepsin B inhibitor was spotted onto the tissue cold, before thawing the 
tissue on the plate.  The tissue was placed on the plate and the inhibitor deposited 
manually while in the cryostat.  Upon deposition the inhibitor spread and essentially 
thawed the tissue onto the plate.  The tissue was then thaw mounted and analyzed using 
MALDI mass spectrometry for presence of m/z 8451.  Figure 19a shows that addition of 
“cold” inhibitor did not prevent the appearance of m/z 8451.   
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Since the deposition of the inhibitor in the cryostat appeared to anneal the tissue 
to the plate it was thought that this action could have provided enough heat to cleave 
ubiquitin ex vivo or that the inhibitor is not effective at this temperature.  To address this 
issue, ubiquitin mixed with the inhibitor was deposited onto a MALDI target and allowed 
to dry.  Rat kidney tissue was then overlaid on top of the spots and analyzed using mass 
spectrometry.  Comparison of the spectra from tissue with ubiquitin and the inhibitor 
underneath versus just the ubiquitin underneath revealed the presence of the mass 
corresponding to the ubiquitin-t (Figure 19b).  Our previous work demonstrated that the 
cleavage of exogenous ubiquitin was inhibited by the addition of the same cathepsin B 
inhibitor at room temperature.  Taken together it can be concluded that cleavage of 
ubiquitin did not occur upon thaw mounting of the tissue. 
The next step in the sample handling process where this cleavage could occur is 
during vacuum desiccation of the tissue.  Tissue is usually kept in the desiccator for ~2 
hrs for optimal drying and matrix crystal formation.  If cleavage of ubiquitin was 
occurring or was enhanced in the desiccator, it is expected that an increase in intensity of 
this ion over time would be observed.  To test this hypothesis, the kidney tissue was 
washed after 5, 10, 20, 30, 60, and 120 minutes in the desiccator and analyzed on the 
mass spectrometer.  After averaging the spectra from five spots on each tissue and 
plotting the intensity of m/z 8451 with the standard error from each tissue, no clear trend 
can be seen although the highest intensity for the ion was observed after 120 minutes 
(Figure 20).  These results led to the conclusion that the cleavage of ubiquitin is not an 
artifact of the sample handling. 
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Ubiquitin cleavage in vivo 
To investigate the possibility that this cleavage occurs in vivo, a rat was dosed 
with a cathepsin B inhibitor and then assayed for presence of m/z 8451.  One rat was 
dosed with 1 ml of 1mg/ml CA074Me, a cell permeable cathepsin B inhibitor, five times 
every six hours for a final dose of 5mg due to the enzyme kinetics [119].  The structure of 
the nonderivatized inhibitor is found in Figure 21.  MALDI images comparing a kidney 
from a control (saline dosed) and dosed rat show a noticeable difference in the 
appearance of cleaved ubiquitin (Figure 22).  The images show that the animal dosed 
with CA074Me showed a marked inhibition in the cleavage of ubiquitin, demonstrating 
that ubiquitin is cleaved by cathepsin B in vivo.   These data correspond to a decrease in 
cathepsin B activity as determined by a fluorometric assay (Figure 23).  Though 
CA074Me is reported to inhibit CATB specifically, Cathepsin L activity was assayed as 
well since our in vitro cleavage studies indicated this protease could cleave ubiquitin as 
well.  The results do show a decrease in CATL activity but not to the extent of CATB 
(Figure 24).    
It has been shown that gentamicin treatment inhibits the activity of cathepsin B 
[52].  These data are consistent with the hypothesis that gentamicin inhibits CATB 
activity, thereby decreasing the production of ubiquitin-t in drug treated samples.  To 
support this hypothesis, we performed a CATB activity assay.  Since I previously 
demonstrated that CATL can produce ubiquitin-t in vitro, we subsequently performed a 
CATL activity assay.  The results indicate a significant decrease in CATB activity as a 
result of drug treatment suggesting the corresponding decrease in ubiquitin-t was as a 
result of decreased CATB activity (Figure 24). 
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Cathepsin B 
Cathepsin B is a dipeptidyl carboxypeptidase that functions optimally at acidic 
pH.  It is translated as a 37kDa propeptide in rat and then cleaved to become an active 
28kDa protein.  This enzyme is unique in that it has an occluding loop that partially 
blocks key residues in the active site (Figure 26). This structural moiety limits access and 
essentially allows two residues to enter into the enzyme‟s active site, effectively allowing 
CATB to remove C-terminal dipeptides [120].  Its specificity is such that it prefers a 
basic and hydrophobic amino acid at the P1 and P2 site respectively [121]. This 
information correlates well with the structure of ubiquitin and its subsequent cleavage 
fragments as determined by our in vitro experiments (Figure 27).  Immunohistochemistry 
experiments have revealed an increased expression of CATB in the kidney cortex [122] a 
finding that correlates well with our imaging data. 
In summary, it has been demonstrated that the removal of the C-terminal glycines 
from ubiquitin, and subsequent inactivation, is facilitated by cathepsin B in vivo.  This 
cleavage can be recapitulated directly on tissue and by utilizing imaging mass 
spectrometry, the localization of this cleavage product can be determined.  The data 
suggests that the decrease in ubiquitin-t seen as a result of drug treatment is due to a 
decrease in cathepsin B activity.  This work not only further suggests the role of 
lysosomal injury in cortical toxicant nephropathy, but it opens the door for further 
investigation into ubiquitin storage and function. 
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Ubiquitin-t in the context of other work in the laboratory 
 The discovery of ubiquitin-t as a marker of drug toxicity was surprising 
and this led us to examine other diseases that were characterized as having altered 
cathepsin B activity-cancer.  Cathepsin B is known to be increased in several forms of 
cancer and is thought to serve multiple roles in progression [123].  Defects in 
ubiquitination itself have been linked to cancer pathogenesis [124-126].  In a comparison 
of normal breast stroma to desmoplastic tumor stroma from 17 human breast tumors, 
ubiquitin-t was identified as having a >5 fold increase in tumor stroma as determined by a 
student‟s T-test [127].  Additionally, when the ratio of ubiquitin-t to ubiquitin is 
compared in 52 invasive breast cancer tissue samples, the patients with a higher grade 
cancer also had a higher percentage of ubiquitin-t in their MALDI profiles (Figure 28) 
[128].  In an analysis of lymph nodes from 52 patients with stage III melanoma and a 
median survival time of 19.9 months, ubiquitin-t was identified as an indicator of poor 
survival (Figure 30) [129].  In work done to analyze the tumor margin in clear cell renal 
cell carcinoma (CCRCC), ubiquitin-t was not only able to classify high grade vs. low 
grade with a 71% accuracy, but it was also one of the features that changed well after the 
histological tumor margin (Figure 31) [130].  These findings not only underscore the role 
of CATB in cancer progression but now also suggest a link to ubiquitin.  In fact, 
disregulation of the ubiquitin-system has been documented in cancer and is reviewed in 
[131].  This work adds another layer of complexity to the ubiquitin/cancer relationship 
that could potentially lead to discovery of a new drug target.  
 Though the focus of the work in this thesis was on the kidney, the discovery of 
ubiquitin-t in various cancer tissues was a rather curious one that led us to examine its 
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spatial localization in other tissues.  Compiling data from our lab, I found ubiquitin-t was 
localized in the area surrounding the embryo in a mouse implantation site [132], in the 
granular layer of the brain, and in the initial segment of the epididymus [133] (Figure 
32).   
 
Ubiquitin-t Origin 
The observation that ubiquitin can interact and subsequently become truncated by 
cathepsin B is a surprising one.  Traditionally, it was not thought that ubiquitin entered 
the lysosome.  Deubiquitinases (DUB) have extensively been shown to remove ubiquitin 
before entering that particular organelle so as to facilitate recycling [134].  But, recently 
ubiquitinated proteins have been found in exosomes [135] and free ubiquitin in 
lysosomes of CATB and CATL null brains [136].  These data suggest a faulty DUB or 
possibly entry into the lysosome by another method, either autophagy or receptor-
mediated endocytosis, both of which were discussed in Chapter III, indicating 
extracellular ubiquitin.   
The concept of extracellular ubiquitin is a relatively new and not yet understood 
phenomenon.  Ubiquitin is secreted from human and mouse embryos [137], cultured 
leptomeningeal cells [138], as well as neuroblastoma cells [139] and the proteasome 
found in human alveolar space [140].  Ubiquitin has been detected in human seminal 
plasma [141], serum and plasma as a result of infection or disease [142-147], bovine 
epididymal fluid [148], and a 1-72 amino acid form of ubiquitin detected by MALDI in 
cerebral spinal fluid [149].  This information led to the hypothesis that the origin of 
ubiquitin-t could be a result of extracellular uptake and subsequent cleavage. 
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Recently Majetschak and colleagues demonstrated uptake of extracellular 
ubiquitin by human acute monocytic leukemia cells [150].  They proposed that this 
uptake was regulated by receptor mediated endocytosis.  The receptor remained 
undetermined.  Using the localization of ubiquitin-t as determined from our imaging 
studies, as well as the finding that half of the proteins indentified from our drug toxicity 
study were ligands of the megalin receptor, we hypothesized that megalin was the 
endocytic receptor responsible for uptake and subsequent cleavage of ubiquitin.  Megalin 
is a 600kDa, single transmembrane receptor that binds low molecular weight proteins and 
transports them to lysosomes.  It has been heavily studied and reviewed [151].  
Importantly, megalin is expressed in the initial segment of the epididymus [152], the 
endometrium and oviduct [153-155], kidney proximal tubule cells [156], and brain 
capillaries and choroid plexus [157] which correlates quite nicely with our imaging data.  
Interestingly, cathepsin B was recently identified as a ligand of the megalin receptor 
[158]. 
To test the hypothesis that ubiquitin-t was a result of extracellular ubiquitin being 
endocytosed through the megalin receptor and targeted to the lysosome where it is 
cleaved by CATB, fluorescence studies were performed with a cell line known to express 
high amounts of megalin [159, 160].  I was able to demonstrate uptake of ubiquitin in rat 
yolk sac epithelial cells as evident by green fluorescence (Figure 33a).  Upon addition of 
a megalin blocking antibody (Figure 33b) and receptor associated protein (RAP), a 
chaperone that inhibits interaction with the receptor, (Figure 33c), no fluorescence is 
detected indicating an inhibition of uptake of ubiquitin.  These data suggest that ubiquitin 
is a ligand of the megalin receptor.  Further binding assays using purified megalin and 
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ubiquitin are necessary to demonstrate direct binding.  Though cleavage as a result of 
uptake has not been directly proven, at the very least these data suggest ubiquitin-t is a 
marker for megalin localization. 
Addition of gentamicin, another known ligand of megalin also prevented uptake 
of ubiquitin (Figure 33d).  This suggests that the decrease we observed in ubiquitin-t as a 
result of drug treatment could not only be due to inhibition of CATB activity as discussed 
in the last chapter, but possibly because of gentamicin inhibiting uptake of ubiquitin.  
Further work is necessary to determine which mechanism is responsible. 
 
Ubiquitin-t function 
 Due to the nature of the truncation indicative of ubiquitin-t, its function is 
not likely associated with the canonical proteasomal degradation pathway.  This suggests 
a novel function.  It was proposed that ubiquitin-t was a storage form of ubiquitin to 
prevent unnecessary ubiquitination.  In brief, cathepsin B would cleave ubiquitin in the 
lysosome when ubiquitination isn‟t needed.  The product would then be recycled back out 
to the cytosol, where it would remain inactivated pending a signal for ubiquitination and 
subsequent ligation of the C-terminal glycines back onto ubiquitin.  To test this 
hypothesis we added 
13
C labeled diglycine to cathepsin B cleaved ubiquitin with excess 
ATP in solution (cell free extract) and directly on tissue.  A peak corresponding to full 
length ubiquitin was not found (data not shown).  This indicated that under the conditions 
used in our experiment, the glycine residues could not be added back onto ubiquitin-t, 
suggesting that this does not occur in vivo.   
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Additionally, Goncalves et al. suggested that the cleaved and native ubiquitins 
have different binding partners, suggesting a role in cell signaling [115].  Further work 
will need to be done to elucidate this protein‟s intracellular function.   
Alternatively, ubiquitin-t could be transcytosed out of the cell.  It was recently 
shown that megalin mediates transcytosis of thyroglobulin, a novel function for this 
receptor [161].  Though in this case, uptake of thyroglobulin by megalin was used to 
bypass the lysosomal degradative pathway, it is possible that megalin not only facilitates 
cleavage of ubiquitin but also mediates its export from the cell.  Transcytosis experiments 
like those performed for thyroglobulin should be done to test this hypothesis. 
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Figure 16.  Localization of cleaved ubiquitin in rat kidney.  MALDI images were 
obtained from rat kidney as described in the text at 250 µm spatial resolution. Cleaved 
ubiquitin is along the outer edge of the kidney (cortex) whereas full length ubiquitin is 
found further inside  the kidney (medulla).  Scale bar=2mm.   
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Figure 18.  In vitro cleavage of ubiquitin.  MALDI spectra from a time course study 
with various carboxypeptidases.  Samples were prepared as described in the text.  The 
resulting spectra from each time point was overlayed and displayed for each enzyme as 
labeled.  Though all enzymes tested produced desGG ubiquitin as indicated on each 
spectrum, cathepsin B effectively cleaved the residues completely and as quickly as 5 
minutes after incubation.  Cathepsin B was the only enzyme tested that removed the 
preceeding dipeptide LR as well as indicated on the spectrum. 
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Figure 19.  Effect of addition of cathepsin B inhibitor on endogenous ubiquitin 
cleavage.  Representative MALDI spectra from analysis of rat kidney with the addition 
of a CATB inhibitor applied a) at ~-20
o
C, prior to thaw mounting and b) on the MALDI 
plate and allowed to dry at room temperature prior to thaw mounting of the tissue. 
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Figure 20.  Time course study on the effect of dessication on cleavage of ubiquitin.  
Rat kidney sections were thaw mounted and placed in a vacuum dessicator for the 
indicated times before ethanol washing and downstream analysis.  Five matrix spots per 
section were averaged and the average intensity of ubiquitin-t plotted as a bar graph with 
the associated error.  The analysis was performed in duplicate with the resulting data 
displayed as pairs of bars at each time point. 
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Figure 21.  Structure of CA074. Inhibitor is shown in its proposed binding orientation 
to CATB. Reprinted with permission from [162] 
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Figure 22.  Inhibition of cleavage of ubiquitin in vivo.  MALDI kidney image of a 
control and CA074ME dosed animal.  Animals were dosed i.p. with empty vector (saline 
and DMSO) or CA074ME, a cathepsin B inhibitor.  Samples were prepared and analyzed 
as described in the text.  Resulting images were acquired at 250 µm spatial resolution.  
Localization of m/z 4965 is shown as a control.  A decrease in the intensity of m/z 8451 
is demonstrated in the dosed animal. 
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Figure 23.  Cathepsin B and L Fluorometric Activity Assay from CA074Me treated 
sample.  Kidneys from control and CA074Me treated rats were assayed for CATB and 
CATL activity as described in the text.  Analysis was done in triplicate and the average 
result plotted as a bar graph with the corresponding error.  A significant decrease in 
CATB activity is observed in the CA074Me treated sample.  CATL activity was 
decreased as well but not to the extent of CATB. 
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Figure 24.  CATB and CATL activity assay from antibiotic treated samples.   
Kidneys from control and drug (kan-kanamycin; gent-gentamicin) treated rats were 
assayed for CATB and CATL activity as described in the text.  Analysis was done in 
triplicate and the average result plotted as a bar graph with the corresponding error.  A 
significant decrease in CATB activity is observed in the drug treated samples.  CATL 
activity was decreased in the kanamycin sample as well but not to the extent of CATB.
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Figure 25.  Crystal structure of cathepsin B (EC 3.4.22.1; 1HUC from PDB). 
Red-Occluding loop (Ile105–Pro126) and symbols of its crucial residues. Green-Side 
chains forming salt bridges (Asp22↔ His110) and pink (Arg116↔ Asp224); Yellow- 
catalytic cleft; Blue-catalytic center.  Reprinted with permission from [163]. 
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Figure 26.  Diagram of cathepsin B specificity with respect to ubiquitin cleavage.  C-
terminal peptide of ubiquitin shown with cleaved residues in red after a a) five minute 
and b) overnight incubation with cathepsin B.  Top schematic outlines the preferred 
amino acids and their positions in the substrate.  +: scissile bond 
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Figure 27.  Comparative analysis of the ratio of ubiquitin-t to ubiquitin in invasive 
mammary carcinoma.  52 samples from patients with invasive mammary carcinoma 
were analyzed by direct tissue MALDI MS.  The ratio of the intensity of the ion 
corresponding to ubiquitin-t (m/z 8451) to ubiquitin (m/z 8565) was determined and 
expressed as a percentage.  Overall, higher grade samples clustered together and have a 
higher percentage ubiquitin-t.  G1-grade 1; G3-grade 3; yellow-low grade; white-high 
grade. Figure courtesy of Erin Seeley  [128].  
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Figure 28.  Survival analysis of metastatic melanoma patients expressing m/z 8451 
(ubiquitin-t).  Lymph nodes from 52 patients with stage III melanoma were analyzed by 
direct tissue MALDI MS.  Patients with a higher intensity of m/z 8451 had a lower 
survival probability than those exhibiting a lower intensity of m/z 8451.  Red line-lowest 
intenstity quartile; Black line-highest intensity quartile. Figure courtesy of William 
Hardesty [129]. 
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Figure 29.  Ubiquitin-t surpasses histological tumor margin.  LOWESS plot of m/z 
8451 from clear cell renal cell carcinoma highlighted in red.  This feature changes well 
beyond the histologically defined tumor margin. Figure adapted from [130].  
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CHAPTER V 
 
DISCUSSION AND CONCLUSION 
 
Overview 
 This chapter will discuss the implications of the work as well as provide a 
summary of the work accomplished.  Additionally, thoughts as to where the work is 
headed will be presented. 
 
Protein Markers of Nephrotoxicity 
 This study utilized MALDI MS to profile and image kidneys from antibiotic 
treated rats for indicators of damage.  Twelve proteins were identified as being 
differentially expressed as a result of gentamicin and kanamycin treatment.  There are 
three points to consider when examining this data.  First, though these changes were 
detected in the cortex, a comparison of data obtained from the medulla revealed 
statistically significant changes, suggesting that though the cortex is the primary site of 
damage, there are secondary effects in the medulla.  This opens the door for further 
analysis of the interplay between damage in the cortex and the medulla. 
 Second, out of the twelve proteins identified, only three were unique to either 
gentamicin or kanamycin treatment.  The overlap in the protein markers was expected 
since the drugs are in the same class, but the discovery that some proteins exhibited 
changes only in response to a single drug‟s treatment was intriguing.  This suggests that 
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there could be unique mechanisms of damage for each nephrotoxicant adding credence to 
the need for further research. 
 Third, all of the proteins identified can be linked to proposed mechanisms of 
toxicity.  This not only speaks to the utility of the technology to detect changes that are 
relevant to disease, but to the promise of expression proteomics.  The idea that one can 
assess the protein changes associated with a disease and subsequently develop a 
hypothesis to gain mechanistic insight is an emerging one with data mounting daily 
[REF].  This study was a true example of utilizing expression proteomics to shed 
mechanistic insight.  Ub-t was discovered as a cortical marker of antibiotic induced 
nephrotoxicity.  Through a series of experiments it was determined that this protein was 
not an experimental artifact as previously reported [50] but was produced in vivo by 
CATB.  It has previously been demonstrated that gentamicin decreases CATB and CATL 
activity [52].  It was therefore hypothesized that the decrease in Ub-t observed in the 
kidney cortex of drug treated animals, was due to inhibition of CATB by gentamicin.  
Preliminary data to this end was presented.   
 Adding proteins to the current caudre of markers will serve to enhance as well as 
potentially expedite the diagnosis of damage.  Traditional protein markers do not exhibit 
changes until the onset of damage [2].  Interest is mounting in the potential to detect 
damage earlier to not only save money in the drug discovery process, but to enhance 
quality of life as well.  The promise of this technology identifying an early marker of 
disease was demonstrated with the finding that lysozyme, a lysosomal protease, was 
increased in the kidney cortex of antibiotic treated rats at a dose and time point where 
traditional biochemical indicators of toxicity were lacking. 
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Future Work 
 More extensive identification as well as further validation and quantitation of the 
proteins identified as markers of gentamicin and kanamycin induced nephrotoxicity is 
necessary for their use in clinical diagnostics.  Part of the difficulty in identifying many 
of the markers in this study is that many of them could possibly be post-translationally 
modified as demonstrated with the discovery of Ub-t and transthyretin discussed 
elsewhere [33]. Efforts to identify the remaining markers will need to focus in this area.  
Validation could be achieved with a number of antibody based techniques including 
immunohistochemistry and immunoprecipitation or in situ hybridization.  Once the 
markers are validated their presence in urine should be monitored to provide a 
noninvasive diagnosis tool.  Urine analysis has been demonstrated for this application 
before [164].   
Additionally, a more refined analysis with a smaller laser size would be 
advantageous due to the fine structure of the nephron.  This would provide deeper levels 
of understanding of not only what changes are occurring in the kidney, but where, 
thereby adding specificity and perhaps gaining new insight into mechanism of toxicity. 
 The integration of these protein markers into other known proteomic, genomic, 
and metabonomic [165] markers should be explored.  A query of lipidomic features could 
also provide beneficial information.  In particular, the analysis of differential 
phospholipid expression should be examined.  One of the proposed mechanisms of 
antibiotic induced nephrotoxicity is phospholipidosis [166-168].  Aminoglycosides such 
as gentamicin, are hydrophilic, polycationic drugs which bind to negatively charged 
phospholipid bilayers and subsequently inhibit enzymes responsible for phospholipid 
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metabolism [166].  This accumulation of phospholipids is referred to as phospholipidosis.  
An analysis of the types and locations of phospholipids differentially expressed as a 
result of drug treatment would be worthwhile.  Though several methods exist to image 
phospholipids directly from tissue by MALDI MS [169], a recent technique demonstrated 
the power of a dry coating method [28].  This method was used to examine the spatial 
and temporal location of phospholipids involved in embryo implantation [132]. 
 
In situ Assessment of Endogenous Enzyme Activity 
 As discussed previously, cathepsins are lysosomal enzymes that play an 
instrumental role in protein degradation.  They can act as endo- or exoproteinases, and 
are mostly active in acidic environments [170, 171].  Cathepsin B, one of the 11 cysteine 
cathepsins, is a lysosomal dipeptidyl carboxypeptidase [110].   It is constitutively 
expressed by all cells and though originally thought to have broad substrate specificity, it 
was recently shown to play a significant role in Alzheimer‟s [172] and cancer [123, 173].  
Therefore considerable interest in assessing this and other cathepsins‟ activities has 
grown.   
Current methods to assess this enzyme and other members of this enzyme 
family‟s activity rely on homogenization of tissue and use of a fluorescently tagged 
substrate [174].  In brief, the homogenate is pre-incubated with the tagged substrate at 
37
o
C for ~ 1 hour where hydrolysis of the tag occurs upon interaction with the enzyme.  
The free tag‟s fluorescence can be detected and quantified using a fluorescence plate 
reader.  Presumably, the fluorescent tag only becomes activated upon cleavage by a 
cathepsin.  The specificity of these methods relies on specialized substrates to assess 
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activity for each cathepsin by an indirect measurement which could become costly in a 
large scale analysis.  This technique also does not lend itself to visualization of enzyme 
activity across a tissue section, something that could become important when assessing 
tumor margins. 
MALDI IMS has been used to assess protein, peptide, and lipid localization [14, 
25, 175-178], detect biomarkers of drug toxicity [66], assess drug localization [21, 179, 
180], and to identify proteins directly from tissue [41].  The latter application uses 
exogenous enzyme to identify proteins in a tissue section.  The utilization of IMS to 
assess endogenous enzyme activity directly from tissue sections allows for a quick, high-
throughput, label-free analysis while maintaining the spatial localization of the enzymatic 
products.  This dissertation represents the first application of IMS for in situ analysis of 
cathepsin B activity.  This methodology can be applied to various other substrates as 
demonstrated in Figure 32 with the Hep B peptide.  By spotting the peptide with the 
CATB activating buffer onto the kidney cortex, the cleavage products were observed.  An 
image can be reconstructed much the same as the Ub data was.  The methodology can 
also potentially be expanded to assess the activity of other enzymes with the 
corresponding activating buffer and substrate.   This tool will allow pathologists to 
register tissue morphology or type directly to endogenous enzyme activity, further aiding 
in diagnosis of disease.   
 
Conclusion 
 In this study, MALDI MS was used to assess differential protein expression as a 
result of antibiotic treatment in rat kidneys.  Through profiling and imaging mass 
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spectrometry protein markers of drug-induced nephrotoxicity were identified.  This 
analysis led to the first reported discovery of an in vivo C-terminal truncation of 
ubiquitin.  The promise of not only further exploring the data generated from this study 
but also the impact of this technology onto the field of drug discovery is exciting and its 
implications will be seen in years to come. 
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Figure 32.  Hep B Pre-S Region Fragment in vitro and in situ cleavage by cathepsin 
B.  Hep B Pre-S Region Fragment was digested with cathepsin B in activating buffer in 
an overnight in vitro assay (top).  The assay resulted in three peaks labeled 1) 1-22 
fragment 2) 1-25 fragment and 3) full length fragment.  After manual deposition of this 
peptide in four spots of the kidney cortex, the same fragments from the in vitro cleavage 
assay can be seen in the resulting spectra as well as one additional peak that could be the 
result of cleavage by another enzyme (bottom).    
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